Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.43)
# 293
Out of 5,182 analysts
90
Total ratings
55.7%
Success rate
20.43%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $110 → $121 | $102.62 | +17.91% | 5 | Apr 15, 2026 | |
| BIIB Biogen | Maintains: Hold | $193 → $189 | $187.88 | +0.60% | 7 | Apr 13, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Hold | $56 → $53 | $52.83 | +0.32% | 5 | Mar 31, 2026 | |
| IVA Inventiva | Initiates: Buy | $13 | $5.21 | +149.52% | 1 | Mar 19, 2026 | |
| SEPN Septerna | Maintains: Buy | $34 → $35 | $24.97 | +40.17% | 2 | Mar 11, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $47.48 | +15.84% | 6 | Mar 4, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $65.48 | +40.50% | 5 | Feb 3, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $87.17 | +33.07% | 6 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $518.74 | +23.38% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $95.47 | -2.59% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $14.75 | +1.69% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $33.39 | +49.75% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $766.02 | +6.00% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $10.42 | +5.57% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $11.56 | +116.26% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $917.65 | +13.12% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $200.95 | +7.99% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $26.67 | +19.99% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $31.23 | +60.10% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.87 | +2,787.70% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.23 | +140.77% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.57 | +117.26% | 1 | Jul 31, 2024 |
Protagonist Therapeutics
Apr 15, 2026
Maintains: Buy
Price Target: $110 → $121
Current: $102.62
Upside: +17.91%
Biogen
Apr 13, 2026
Maintains: Hold
Price Target: $193 → $189
Current: $187.88
Upside: +0.60%
Terns Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: $56 → $53
Current: $52.83
Upside: +0.32%
Inventiva
Mar 19, 2026
Initiates: Buy
Price Target: $13
Current: $5.21
Upside: +149.52%
Septerna
Mar 11, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $24.97
Upside: +40.17%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $47.48
Upside: +15.84%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $65.48
Upside: +40.50%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $87.17
Upside: +33.07%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $518.74
Upside: +23.38%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $95.47
Upside: -2.59%
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $14.75
Upside: +1.69%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $33.39
Upside: +49.75%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $766.02
Upside: +6.00%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $10.42
Upside: +5.57%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $11.56
Upside: +116.26%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $917.65
Upside: +13.12%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $200.95
Upside: +7.99%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.67
Upside: +19.99%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $31.23
Upside: +60.10%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.87
Upside: +2,787.70%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $6.23
Upside: +140.77%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $16.57
Upside: +117.26%